Pricing | |||||
5400 | |||||
3400 | |||||
1800 | |||||
Study Period | 2019-2030 |
Market Size (2023): | USD17Billion |
Market Size (2030): | USD24Billion |
CAGR (2023 - 2030): | 5.00% |
Fastest Growing Region | North America |
Dominating Region | Europe |
Report Features |
Details |
Base Year |
2023 |
Based Year Market Size (2023) |
USD17Billion |
Historical Period |
2019 to 2023 |
CAGR (2023 to 2030) |
5.00% |
Forecast Period |
2023 to 2030 |
Forecasted Period Market Size (2030) |
USD24Billion |
Scope of the Report |
Segmentation by Type SSRIs, SNRIs, Atypical Antidepressants, Tricyclic Antidepressants, Segmentation by Application Mental Health Treatment, Chronic Pain Management, Neurological Disorders, Substance Abuse Treatment, Anxiety Disorders, Sales Channel |
Regions Covered |
|
Companies Covered |
Pfizer, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Merck & Co., Novartis, Sanofi, Otsuka Pharmaceutical, Takeda, Alkermes, Amgen, Lundbeck |
Customization Scope |
15% Free Customization (For EG) |
Delivery Format |
PDF and Excel through Email |